Medtronic plc’s Stock Price Skyrockets to $81.26, Marking an Impressive 4.05% Uptick

Medtronic plc (MDT)

81.26 USD +3.16 (+4.05%) Volume: 9.8M

Medtronic plc’s stock price surges by +4.05% in the current trading session, reaching 81.26 USD with a substantial trading volume of 9.8M, despite a slight YTD decrease of -1.36%, showcasing the stock’s potential for growth and investment viability.

Latest developments on Medtronic plc

Medtronic Plc stock experienced a mix of highs and lows recently, with the company outperforming competitors on a strong trading day following the launch of an AI platform for robotic surgery. Despite being recognized for disability inclusion efforts in the U.S. and U.K., the stock underperformed on Monday, leading to a lowered price target of $85.00 by Truist Financial. However, Medtronic remains a dividend aristocrat worth considering for investment, with potential for profit despite being labeled as an out of favor healthcare stock. Investors are advised to lock in this opportunity while the stock is still perceived as cheap.

Medtronic plc on Smartkarma

Analysts at Baptista Research on Smartkarma are bullish on Medtronic Plc, highlighting the company’s expansion of global operations and supply chain transformation as major drivers of growth. In its fiscal year 2024 Q4 earnings, Medtronic reported significant revenue growth and strong earnings across its four segments, driven by new product innovations in cardiovascular, robotics, diabetes care, and other therapeutic segments.

Furthermore, Baptista Research‘s analysis of Medtronic plc emphasizes data-driven innovations and five major drivers of future growth. The company delivered a solid quarter with mid-single-digit revenue growth exceeding expectations, supported by strength in Core Spine, Cardiac Surgery, Structural Heart, and Cardiac Pacing businesses. Innovation-driven core technologies such as robotics, AI, and closed-loop systems are identified as significant growth propellers, with five AI products already FDA approved.

A look at Medtronic plc Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Medtronic Plc, a company that develops medical products, has received positive scores across the board according to Smartkarma Smart Scores. With high scores in Value, Dividend, and Growth, Medtronic is poised for long-term success in the market. While the company scored slightly lower in Resilience and Momentum, the overall outlook remains strong for Medtronic.

Medtronic Plc‘s focus on developing therapeutic and diagnostic medical products has positioned the company well for the future. With a solid track record in bradycardia pacing, heart failure management, and other key areas, Medtronic’s global presence ensures a wide reach for its products. The company’s strong scores in Value, Dividend, and Growth indicate a promising long-term outlook, despite slightly lower scores in Resilience and Momentum.

Summary: Medtronic, PLC develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma